ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2702

Incidence, Prevalence, Mortality and Comparison of the Acr/EULAR 2013 Classification Criteria with 1980 Criteria in Physician Diagnosed Systemic Sclerosis: Results from a Population Based Cohort (1980-2016)

Avneek Singh Sandhu1, Cynthia S. Crowson2, Philippe R. Bauer3, Eric L. Matteson4 and Ashima Makol1, 1Rheumatology, Mayo Clinic, Rochester, MN, 2Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 3Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, 4Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: classification criteria, morbidity and mortality and population studies

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Systemic Sclerosis and Related Disorders – Clinical Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic Sclerosis (SSc) is a complex and heterogenous chronic inflammatory disease characterized by widespread fibrosis of the skin and visceral organs, microvascular injury and evidence of immune system activation. We aimed to determine the incidence, prevalence and mortality of physician diagnosed SSc in a population-based  cohort and to evaluate the performance of the ACR/EULAR 2013 Classification criteria vs. 1980 ACR criteria in classifying patients with SSc.

Methods: Medical records of patients with a diagnosis or suspicion of SSc in a geographically well-defined area from Jan 1, 1980 to Dec 31, 2016 were reviewed to identify incident cases of SSc (defined by physician diagnosis). Prevalent cases of SSc on Jan 1, 2015 were also identified. Incidence and prevalence rates were age and sex adjusted to the 2010 US white population. Survival rates were compared with expected rates in the general population. Fulfillment of the 1980 and 2013 classification criteria was ascertained.

Results: 79 incident cases of SSc (90% female, 87% Caucasians, mean age at diagnosis 55.8 +/- 16 y) from 1980-2016 and 49 prevalent cases on Jan 1, 2015 were identified. . The overall age- and sex-adjusted annual incidence for 1980-2016 was 2.7 (95% C.I. 2.1- 3.3) per 100,000 population (age-adjusted incidence was 4.6 (95% CI: 3.5-5.7) per 100,000 for females and 0.6 (95% CI: 0.2-1.1) per 100,000 for males), with no change in incidence over time. The age- and sex-adjusted prevalence on January 1, 2015 was 47.4 (95% CI: 34.1 -60.7) per 100,000 population. 64 of 79 (81%) patients fulfilled the 2013 classification criteria, while only 48% fulfilled the 1980 criteria. All but 1 patient that fulfilled the 1980 criteria also fulfilled the 2013 criteria. At SSc diagnosis, 74 (94%) patients had Raynaud’s, 13/44 (30%) had abnormal nail fold capillaries, 16/33 (48%) had digital ulcers/pitting scars, 43 (54%) had sclerodactyly, 39 (49%) had telangiectasias, 8 (10%) had pulmonary hypertension, and 7 (9%) had interstitial lung disease. 66 patients had limited cutaneous SSc, 11 had diffuse cutaneous SSc and only 2 had Sine scleroderma. 39 patients had a positive autoantibody for SSc : ACA in 29, anti Scl-70 in 8 and anti RNA-polymerase III in 2. Mortality among SSc patients was significantly higher in comparison to the general population (standardized mortality ratio, 2.24; 95% C.I., 1.52-3.18; Figure).

Conclusion: The average incidence of SSc in this population-based cohort was 2.7 per 100,000 population with no evidence of a change in incidence over the 36 year period of study. The new 2013 classification criteria perform significantly better than the 1980 criteria, but failed to classify 19% of patients in this cohort. Overall survival of patients with SSc is worse than the general population with no evidence of improved survival over time, indicating an unmet need for early diagnosis and more aggressive management.


Disclosure: A. S. Sandhu, None; C. S. Crowson, None; P. R. Bauer, None; E. L. Matteson, None; A. Makol, None.

To cite this abstract in AMA style:

Sandhu AS, Crowson CS, Bauer PR, Matteson EL, Makol A. Incidence, Prevalence, Mortality and Comparison of the Acr/EULAR 2013 Classification Criteria with 1980 Criteria in Physician Diagnosed Systemic Sclerosis: Results from a Population Based Cohort (1980-2016) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/incidence-prevalence-mortality-and-comparison-of-the-acr-eular-2013-classification-criteria-with-1980-criteria-in-physician-diagnosed-systemic-sclerosis-results-from-a-population-based-cohort-1980/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/incidence-prevalence-mortality-and-comparison-of-the-acr-eular-2013-classification-criteria-with-1980-criteria-in-physician-diagnosed-systemic-sclerosis-results-from-a-population-based-cohort-1980/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology